EDGE funds development of Heparinex drug delivery technology
The Heparosan-based drug delivery system involves conjugating a naturally occurring sugar molecule, heparosan, to a drug. This system helps the drug to stay in the body for longer,
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.
The study published as a research article, ‘Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes’ investigated the details of a novel proteomics based method in detecting inhibition